Literature DB >> 26051204

Evaluation of physical activity reporting in community Diabetes Prevention Program lifestyle intervention efforts: A systematic review.

Yvonne L Eaglehouse1, M Kaye Kramer2, Bonny Rockette-Wagner2, Vincent C Arena3, Andrea M Kriska2.   

Abstract

INTRODUCTION: The Diabetes Prevention Program (DPP) lifestyle intervention has been translated to community settings using the DPP goals of 7% weight loss and 150min of moderate physical activity (PA) per week. Given that PA is a primary lifestyle goal and has been linked to improvements in metabolic health in the DPP, it is important to understand the role that PA plays in translation effort success. The purpose of this review is to thoroughly evaluate the reporting of PA methodology and results in DPP-based translations in order to guide future prevention efforts.
METHODS: PubMed and Ovid databases were searched to identify peer-reviewed original research articles on DPP-based translations for adults at-risk for developing diabetes or cardiovascular disease, limited to English language publications from January 2002-March 2015.
RESULTS: 72 original research articles describing 57 translation studies met eligibility criteria. All 57 study interventions included a PA goal, 47 studies (82%) collected participant PA information, and 34 (60%) provided PA results.
CONCLUSIONS: Despite PA being a primary intervention goal, PA methodology and results are under-reported in published DPP translation studies. This absence and inconsistency in reporting PA needs addressed in order to fully understand translation efforts' impact on participant health.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes mellitus, type 2; Physical activity; Preventive medicine; Public health

Mesh:

Year:  2015        PMID: 26051204     DOI: 10.1016/j.ypmed.2015.05.023

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  6 in total

1.  Impact of a community-based lifestyle intervention program on health-related quality of life.

Authors:  Yvonne L Eaglehouse; Gerald L Schafer; Vincent C Arena; M Kaye Kramer; Rachel G Miller; Andrea M Kriska
Journal:  Qual Life Res       Date:  2016-02-20       Impact factor: 4.147

2.  The Likely Underestimated Impact of Lifestyle Intervention: Diabetes Prevention Program Translation Examples.

Authors:  Andrea M Kriska; Susan M Devaraj; Kaye Kramer; Jenna M Napoleone; Bonny Rockette-Wagner; Yvonne Eaglehouse; Vincent C Arena; Rachel G Miller
Journal:  Am J Prev Med       Date:  2022-01-12       Impact factor: 5.043

3.  Change in Objectively Measured Activity Levels Resulting from the EMPOWER Study Lifestyle Intervention.

Authors:  B Rockette-Wagner; J Cheng; Z Bizhanova; A M Kriska; S M Sereika; C E Kline; C C Imes; J K Kariuki; D D Mendez; L E Burke
Journal:  Transl J Am Coll Sports Med       Date:  2022

4.  The Impact of Physical Activity on the Prevention of Type 2 Diabetes: Evidence and Lessons Learned From the Diabetes Prevention Program, a Long-Standing Clinical Trial Incorporating Subjective and Objective Activity Measures.

Authors:  Andrea M Kriska; Bonny Rockette-Wagner; Sharon L Edelstein; George A Bray; Linda M Delahanty; Mary A Hoskin; Edward S Horton; Elizabeth M Venditti; William C Knowler
Journal:  Diabetes Care       Date:  2020-11-10       Impact factor: 19.112

5.  The role of Sociodemographic factors on goal achievement in a community-based diabetes prevention program behavioral lifestyle intervention.

Authors:  Susan M Devaraj; Jenna M Napoleone; Rachel G Miller; Bonny Rockette-Wagner; Vincent C Arena; Chantele Mitchell-Miland; Mohammed Bu Saad; Andrea M Kriska
Journal:  BMC Public Health       Date:  2021-10-02       Impact factor: 3.295

6.  Physical Activity Levels in a Community Lifestyle Intervention: A Randomized Trial.

Authors:  Yvonne L Eaglehouse; Bonny Rockette-Wagner; M Kaye Kramer; Vincent C Arena; Rachel G Miller; Karl K Vanderwood; Andrea M Kriska
Journal:  Transl J Am Coll Sports Med       Date:  2016-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.